Focus: Jazz Pharmaceuticals is a publicly-traded specialty pharma company focused on neurology and oncology with ~$3.8B in annual revenue, anchored by blockbuster cannabinoid and narcolepsy franchises.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Jazz Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Jazz Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Jazz Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship asset representing 42% of revenue; peak-stage lifecycle with 15+ years of exclusivity remaining.
Successor to XYREM franchise; peak-stage with extended LOE provides sustained cash flow.
Legacy narcolepsy asset losing market share to XYWAV; faces patent cliff by 2033.
Niche oncology asset with minimal revenue contribution; long patent tail to 2040.
Recently approved biologic HER2-directed antibody; only growth-stage asset in commercial portfolio with expansion potential.
2 discontinued, 0 duplicate formulations not shown
Jazz Pharmaceuticals (JAZZ) sets 2026 AGM on directors, pay and share issuance powers - Stock Titan
Jazz Pharmaceuticals (JAZZ) sets 2026 AGM on directors, pay and share issuance powers Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) CEO donates 600 shares - Stock Titan
Jazz Pharmaceuticals (NASDAQ: JAZZ) CEO donates 600 shares Stock Titan
New narcolepsy and hypersomnia data on low-sodium sleep drug at SLEEP 2026 - Stock Titan
New narcolepsy and hypersomnia data on low-sodium sleep drug at SLEEP 2026 Stock Titan
Coffee, racetracks, beaches and more coffee—inside the ASCO 2026 exhibit floor - Fierce Pharma
Coffee, racetracks, beaches and more coffee—inside the ASCO 2026 exhibit floor Fierce Pharma
Jazz Pharmaceuticals (JAZZ) legal chief sells 1,192 shares under 10b5-1 plan - Stock Titan
Jazz Pharmaceuticals (JAZZ) legal chief sells 1,192 shares under 10b5-1 plan Stock Titan
Director at Jazz Pharmaceuticals (JAZZ) exercises 3,415 stock options - Stock Titan
Director at Jazz Pharmaceuticals (JAZZ) exercises 3,415 stock options Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+1 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo